{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:59:49Z","timestamp":1771232389394,"version":"3.50.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100026676","name":"Rotary District 6920","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100026676","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004460","name":"Rotary International","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004460","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejso.2024.108603","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T22:35:53Z","timestamp":1723502153000},"page":"108603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-8561","authenticated-orcid":false,"given":"Laura","family":"Cortesi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Venturelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Toss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Tamburrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7979-6261","authenticated-orcid":false,"given":"Antonino","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7520-2908","authenticated-orcid":false,"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Bisagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Dominici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2024.108603_bib1","series-title":"I numeri del cancro 2022 AIOM-Registri Tumori Italiani, Intermedia Editore","author":"Fondazione","year":"2022"},{"key":"10.1016\/j.ejso.2024.108603_bib2","unstructured":"NIH National Cancer Institute, Cancer stat facts: female breast cancer, (n.d.)."},{"key":"10.1016\/j.ejso.2024.108603_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10549-010-0805-3","article-title":"Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age","volume":"124","author":"van der Kolk","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108603_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.1088759","article-title":"Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2","volume":"302","author":"King","year":"1979","journal-title":"Science"},{"key":"10.1016\/j.ejso.2024.108603_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1470-2045(17)30891-4","article-title":"Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study","volume":"19","author":"Copson","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100459","article-title":"Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies","volume":"7","author":"Russo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejso.2024.108603_bib7","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/gim.2016.29","article-title":"Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations","volume":"18","author":"D'Andrea","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.ejso.2024.108603_bib8","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cam4.2824","article-title":"A regional population\u2010based hereditary breast cancer screening tool in Italy: first 5\u2010year results","volume":"9","author":"Cortesi","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejso.2024.108603_bib9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/sim.1668","article-title":"A breast cancer prediction model incorporating familial and personal risk factors","volume":"23","author":"Tyrer","year":"2004","journal-title":"Stat Med"},{"key":"10.1016\/j.ejso.2024.108603_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-6-210","article-title":"Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience","volume":"6","author":"Cortesi","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2024.108603_bib11","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1002\/sim.7084","article-title":"Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis","volume":"35","author":"Austin","year":"2016","journal-title":"Stat Med"},{"key":"10.1016\/j.ejso.2024.108603_bib12","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2024.108603_bib13","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41416-021-01597-2","article-title":"Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer","volume":"126","author":"Guzm\u00e1n-Arocho","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2024.108603_bib14","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1200\/JCO.21.00531","article-title":"Risk of late-onset breast cancer in genetically predisposed women","volume":"39","author":"Boddicker","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.breast.2021.09.006","article-title":"Ovarian reserve of women with and without BRCA pathogenic variants: a systematic review and meta-analysis","volume":"60","author":"Gasparri","year":"2021","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2024.108603_bib16","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(96)10109-4","article-title":"Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases","volume":"349","author":"Stratton","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2024.108603_bib17","doi-asserted-by":"crossref","first-page":"R465","DOI":"10.1186\/bcr1025","article-title":"Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2and mutation-negative breast cancer families","volume":"7","author":"Eerola","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejso.2024.108603_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U","article-title":"Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations","volume":"27","author":"Cortesi","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejso.2024.108603_bib19","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA -positive and BRCA -negative breast cancer","volume":"26","author":"Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10549-016-3697-z","article-title":"Low prevalence of HER2 positivity amongst BRCA1 and BRCA2 mutation carriers and in primary BRCA screens","volume":"155","author":"Evans","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108603_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.breast.2022.07.012","article-title":"Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer","volume":"65","author":"Viansone","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2024.108603_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41523-021-00224-w","article-title":"Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants","volume":"7","author":"Lambertini","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejso.2024.108603_bib23","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.3390\/jpm12091404","article-title":"Clustering molecular subtypes in breast cancer, immunohistochemical parameters and risk of axillary nodal involvement","volume":"12","author":"Pereira","year":"2022","journal-title":"J Personalized Med"},{"key":"10.1016\/j.ejso.2024.108603_bib24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12672-023-00732-0","article-title":"Progress and prospects in research and clinical practice of hormone receptor-positive, HER-2-negative breast cancer with BRCA1\/2 mutations","volume":"14","author":"Yan","year":"2023","journal-title":"Discover Oncology"},{"key":"10.1016\/j.ejso.2024.108603_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/tbj.12887","article-title":"Efficacy of anthracycline\/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1\/BRCA2 mutation carriers","volume":"24","author":"Bignon","year":"2018","journal-title":"Breast J"},{"key":"10.1016\/j.ejso.2024.108603_bib26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.19.03292","article-title":"Tbcrc 031: randomized phase II study of neoadjuvant cisplatin versus doxorubicin-cyclophosphamide in germline BRCA carriers with HER2-negative breast cancer (the INFORM trial)","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib27","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib28","article-title":"Platinum-based chemotherapy for early triple-negative breast cancer","volume":"2021","author":"Mason","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejso.2024.108603_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2024.108603_bib30","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10549-023-06904-4","article-title":"Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1\/2 variants","volume":"199","author":"Liu","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108603_bib32","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2000.18.19.3360","article-title":"Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1\/2 mutations","volume":"18","author":"Pierce","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib33","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/jnci\/djad116","article-title":"Contralateral breast cancer risk in patients with breast cancer and a germline- BRCA1\/2 pathogenic variant undergoing radiation","volume":"115","author":"van Barele","year":"2023","journal-title":"J Natl Cancer Inst: J Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2024.108603_bib34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","article-title":"Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers","volume":"34","author":"van den Broek","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib35","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1200\/JCO.22.01239","article-title":"Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2","volume":"41","author":"Yadav","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2024.108603_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-010-0894-z","article-title":"Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy","volume":"121","author":"Pierce","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2024.108603_bib37","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clbc.2019.08.003","article-title":"Pathology of BRCA1- and BRCA2-associated breast cancers: known and less known connections","volume":"20","author":"Fountzilas","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejso.2024.108603_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000479155","article-title":"Evaluation of transvaginal ultrasound plus CA-125 measurement and prophylactic salpingo-oophorectomy in women at different risk levels of ovarian cancer: the Modena study group cohort study","volume":"93","author":"Cortesi","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.ejso.2024.108603_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/GME.0000000000001883","article-title":"The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance","volume":"29","author":"Grandi","year":"2022","journal-title":"Menopause"},{"key":"10.1016\/j.ejso.2024.108603_bib40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2407-10-90","article-title":"Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer","volume":"10","author":"Cortesi","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2024.108603_bib41","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1158\/1078-0432.CCR-07-4100","article-title":"Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers","volume":"14","author":"Aaltonen","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2024.108603_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2022\/1447545","article-title":"Contralateral prophylactic mastectomy among women with pathogenic variants in BRCA1\/2: overall survival, racial, and ethnic differences","volume":"2022","author":"Makhnoon","year":"2022","journal-title":"Breast J"},{"key":"10.1016\/j.ejso.2024.108603_bib43","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk\u2010reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk\u2010Gerritsen","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejso.2024.108603_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-013-2583-1","article-title":"Contralateral mastectomy improves survival in women with BRCA1\/2-associated breast cancer","volume":"140","author":"Evans","year":"2013","journal-title":"Breast Cancer Res Treat"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324006553?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798324006553?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T02:20:54Z","timestamp":1726798854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798324006553"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0748798324006553"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108603","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can contralateral prophylactic mastectomy and oophorectomy increase survival in BRCA-related breast cancer? Results from the Italian MUTina study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2024.108603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108603"}}